Cadrenal Therapeutics
CVKD
20 hedge funds and large institutions have $1.57M invested in Cadrenal Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
91% more capital invested
Capital invested by funds: $824K → $1.57M (+$750K)
18% more funds holding
Funds holding: 17 → 20 (+3)
2.1% more ownership
Funds ownership: 3.48% → 5.58% (+2.1%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$246K |
| 2 |
LPL Financial
San Diego,
California
|
+$176K |
| 3 |
JP Morgan Chase
New York
|
+$92.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$69.9K |
| 5 |
Morgan Stanley
New York
|
+$5.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
-$23.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.64K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$161 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$12 |
CVKD Hedge Fund Activity: Q3 2025 in Review
20 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q3 2025, worth a combined $1.57M — up 91% from $824K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CVKD positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $246K. The largest seller was Raymond James Financial, exiting entirely with an estimated $23.1K sold.
- 20 institutional investors held Cadrenal Therapeutics (CVKD) as of Q3 2025, up from 17 in Q2 2025.
- Funds reported $1.57M of Cadrenal Therapeutics stock for Q3 2025, up 91% quarter-over-quarter.
- 5 funds opened new Cadrenal Therapeutics positions in Q3 2025 and 2 closed out, a net change of +3 holders.
- The largest Cadrenal Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $246K added.
- The largest Cadrenal Therapeutics seller in Q3 2025 was Raymond James Financial, an estimated $23.1K sold.
Based on aggregated 13F filings for Q3 2025.